Hydroxyl compounds and compositions for cholesterol management and related uses

A method for treating or preventing aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease septicemia, Syndrome X, thrombotic disorder, modulating C reactive protein, or enhancing bile production in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of formula I

• or a pharmaceutically acceptable salt hydrate, solvate or mixture thereof wherein:
• (a) each occurrence of m is independently an integer ranging from 0 to 5;
• (b) each occurrence of n is independently an integer ranging from 3 to 7;
• (c) X is (CH2)z or Ph, wherein z is an integer ranging from 0 to 4 and Ph is a 1,2-, 1,3-, or 1,4 substituted phenyl group;
• (d) each occurrence of R1, R2, R11 and R12 is independently H, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, phenyl, or benzyl, wherein R1, R2, R11, and R12 are not each simultaneously H;
• and
• (e) each occurrence of Y1 and Y2 is independently (C1-C6)alkyl OH, COOH, COOR3, SO3H,
• wherein:
• (i) Y1 and Y2 are not each simultaneously (C1-C6)alkyl;
• (ii) R3 is (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C1-C6)alkoxy, or phenyl groups,
• (iii) each occurrence of R4 is independently H, (C1-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)alkynyl and is unsubstituted or substituted with one or two halo, OH, C1-C6 alkoxy, or phenyl groups and
• (iv) each occurrence of R5 is independently He, (C1-C6)alkyl, (C2-C6)alkenyl or (C2-C6)alkynyl.

A method of treating or preventing a disease or disorder that is capable of being treated by increasing HDL levels, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of formula I

• or a pharmaceutically acceptable salt, hydrate, solvate or mixture thereof, wherein:
• (a) each occurrence of m is independently an integer ranging from 0 to 5;
• (b) each occurrence of n is independently an integer ranging from 3 to 7;
• (c) X is (CH2)z or Ph, wherein z is an integer ranging from 0 to 4 and Ph is a 1,2-, 1,3-, or 1,4 substituted phenyl group,
• (d) each occurrence of R1, R2, R11, and R12 is independently H, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, phenyl, or benzyl, wherein R1, R2, R11, and R12 are not each simultaneously H;
• and
• (e) each occurrence of Y1 and Y2 is independently (C1-C6)alkyl, OH, COOH, COOR3, SO3H.
• wherein:
• (i) Y1 and Y2 are not each simultaneously (C1-C6)alkyl;
• (ii) R3 is (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C1-C6)alkoxy, or phenyl groups,
• (iii) each occurrence of R4 is independently H, (C1-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)alkynyl and is unsubstituted or substituted with one or two halo, OH, C1-C6 alkoxy, or phenyl groups;
• and
• (iv) each occurrence of R5 is independently H, (C1-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)alkynyl.

A method of treating or preventing a disease or disorder that is capable of being treated by lowering LDL levels, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of formula I

• or a pharmaceutically acceptable salt, hydrate, solvate or mixture thereof, wherein:
• (a) each occurrence of m is independently an integer ranging from 0 to 5;
• (b) each occurrence of n is independently an integer ranging from 3 to 7;
• (c) X is (CH2)z or Ph, wherein z is an integer ranging from 0 to 4 and Ph is a 1,2-, 1,3-, or 1,4 substituted phenyl group,
• (d) each occurrence of R1, R2, R11 and R12 is independently H, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, phenyl, or benzyl, wherein R1, R2, R11, and R12 are not each simultaneously H;
• and
• (e) each occurrence of Y1 and Y2 is independently (C1-6)alkyl, OH, COOH, COOR3, SO3H,
• wherein:
• (i) Y1 and Y2 are not each simultaneously (C1-C6)alkyl;
• (ii) R3 is (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C1-C6)alkoxy, or phenyl
• (iii) each occurrence of R4 is independently H, (C1-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)alkynyl and is unsubstituted or substituted with one or two halo, OH, C1-C6 alkoxy, or phenyl groups, and
• (iv) each occurrence of R5 is independently H, (C1-C6)alkyl (C2-C6)alkenyl, or (C2-C6)alkynyl.